1. Introduction 1.1 Market Definition 2. Research Methodology 3. Executive Summary 4. Key Inferences 5. Market Overview 5.1 Current Market Scenario 5.2 Porter's Five Forces Analysis 5.2.1 Bargaining Power of Suppliers 5.2.2 Bargaining Power of Consumers 5.2.3 Threat of New Entrants 5.2.4 Threat of Substitute Product and Services 5.2.5 Competitive Rivalry within the Industry 5.3 Pipeline Analysis 6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC) 6.1 Market Drivers 6.1.1 Rising Burden of Lifestyles Diseases 6.1.2 Technological Advancements towards Personalized Cardiovascular Medicines 6.1.3 Augmentation of Novel Drug Delivery Systems 6.2 Market Restraints 6.2.1 Increasing Adoption of Minimally Invasive Surgeries 6.2.2 Side Effects Associated with Certain Drug Classes 6.3 Market Opportunities 6.4 Key Challenges 7. Market Segmentation 7.1 By Therapeutic Class 7.1.1 Beta Blockers 7.1.2 Calcium Channel Blockers 7.1.3 Nitrates 7.1.4 Angiotensin-converting Enzyme Inhibitors (ACE Inhibitors) 7.1.5 Anti-Platelets 7.1.6 Others 7.2 By Geography 7.2.1 North America 7.2.1.1 US 7.2.1.2 Canada 7.2.1.3 Mexico 7.2.2 Europe 7.2.2.1 France 7.2.2.2 Germany 7.2.2.3 UK 7.2.2.4 Italy 7.2.2.5 Spain 7.2.2.6 Rest of Europe 7.2.3 Asia-Pacific 7.2.3.1 China 7.2.3.2 Japan 7.2.3.3 India 7.2.3.4 Australia 7.2.3.5 South Korea 7.2.3.6 Rest of Asia-Pacific 7.2.4 Middle East & Africa 7.2.4.1 GCC 7.2.4.2 South Africa 7.2.4.3 Rest of MEA 7.2.5 South America 7.2.5.1 Brazil 7.2.5.2 Argentina 7.2.5.3 Rest of South America 8. Competitive Landscape 8.1 Mergers & Acquisition Analysis 8.2 Agreements, Collaborations, and Partnerships 8.3 New Products Launches 9. Key Players 9.1 Amgen 9.2 Bayer 9.3 Eli Lilly and Company 9.4 Gilead 9.5 GlaxoSmithKline Plc. 9.6 Merck & Co., Inc. 9.7 Novartis AG 9.8 Otsuka Pharmaceutical Co. Ltd 9.9 Pfizer Inc. 9.10 Sanofi *List Not Exhaustive 10. Future of the Market

Amgen Bayer Eli Lilly and Company Gilead GlaxoSmithKline Plc. Merck & Co., Inc. Novartis AG Otsuka Pharmaceutical Co. Ltd Pfizer Inc. Sanofi